MedCell Bioscience and NovaThera merge

On June 18, 2008, MedCell Bioscience Ltd. announced its merger with NovaThera Ltd, (Cambridge, UK). The combined company, which will continue to trade under the MedCell Bioscience name, has a post merger valuation of about £30 million.

MedCell BioScience is an innovative healthcare company dedicated to developing new regenerative medicine technologies for the treatment of tendon and ligament injuries.

MedCell Bioscience was advised by Fasken Martineau Stringer Saul with a team led by David Smith and including, among others, Claire Mitchell (corporate) and Paul Yerbury and Rakesh Jhally (tax).